This also applies when working with public relations, public policy, advertising and marketing agencies employed by funding companies or participating in any public media campaigns regarding issues of relevance and importance to brain tumour patients, families and caregivers. The IBTA welcomes the IFPMA Code of Practice, the EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations and other relevant international and national guidelines governing relationships between pharmaceutical/diagnostic/medical device/capital equipment manufacturers and patient organisations and endeavours to work within their recommendations. Where required by the relevant Code of Practice, materials produced by the IBTA may be subject to the company’s certification process. In such cases alterations may only be suggested to ensure the materials comply with the relevant Code of Practice. Any such recommended alterations will not jeopardise the editorial independence and transparency of the IBTA.
Company sponsorship will be publicly acknowledged and, where appropriate, the companies will be kept regularly informed of the progress of the initiative they are supporting.
At the same time, transparency is fundamental to any funds that are accepted by the IBTA to ensure that government, the public, industry, and above all patients and their caregivers, are fully aware of any commercial arrangement that the IBTA has negotiated.
All companies with which the IBTA collaborates will be made aware of this policy and must agree to work within its principles.